Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA has approved Novo Nordisk’s Norditropin FlexPro, a new prefilled growth hormone injection pen to be used by children and adults.
Subscribe to our email newsletter
Novo Nordisk claimed that Norditropin FlexPro has a new dosing mechanism, a user-friendly design which makes it easy to learn and use, and an audible click that confirms that the dose has been delivered.
The company said that Norditropin FlexPro requires no reconstitution and no loading of cartridges. Norditropin FlexPro is available in 5mg/1.5ml, 10mg/1.5ml and 15mg/1.5ml pens.
Novo Nordisk added that in a handling study, 100% of patients found it easy to learn how to use Norditropin FlexPro. 99% of patients found it easy to push the button to dose and 97% felt confident the correct dose was delivered.
Pablo de Mora, global vice president of growth hormone treatment at Novo Nordisk, said: “During our 20 years providing Norditropin growth hormone, we have listened to patients and we understand the importance of providing simple, hassle-free patient care. With the advantages of our new Norditropin FlexPro we are convinced that daily injections will be made even simpler, so patients are better able to achieve their individual treatment goals.”